Recent advances in the diagnosis and treatment of polymyalgia rheumatica

References

• Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant cell arteritis. N Engl J Med. 2002;347:261–271.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Niccoli L, et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 2005;53:33–38.
   PubMed Web of Science ®Google Scholar
• Kremers HM, Reinalda MS, Crowson CS, et al. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol. 2005;32:65–73.
   PubMed Web of Science ®Google Scholar
• Muratore F, Pipitone N, Hunder GG, et al. Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol. 2013 Jul–Aug;31(4 Suppl 78):S86–S92.
   PubMed Web of Science ®Google Scholar
• Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997 Oct;40(10):1873–1878.
   PubMed Web of Science ®Google Scholar
• Pipitone N, Salvarani C. Update on polymyalgia rheumatica. Eur J Intern Med. 2013 Oct;24(7):583–589.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454–1461.
   PubMed Web of Science ®Google Scholar
• Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other infl ammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63:633–639.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Gabriel SE, O’Fallon WM, et al. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970–1991. Arthritis Rheum. 1995;38:369–373.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Macchioni PL, Tartoni PL, et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol. 1987;5:205–215.
   PubMed Web of Science ®Google Scholar
• Doran MF, Crowson CS, O’Fallon WM, et al. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol. 2002;29:1694–1697.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:234–245.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Macchioni P, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 1998;41:1221–1226.
   PubMed Web of Science ®Google Scholar
• Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet. 2013 Jan 5;381(9860):63–72.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Gabriel S, Hunder GG. Distal extremity swelling with pitting edema in polymyalgia rheumatica: report of nineteen cases. Arthritis Rheum. 1996;39:73–80.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Olivieri I, et al. Polymyalgia rheumatica: a disorder of extraarticular synovial structures? J Rheumatol. 1999;26:517–521.
   PubMed Web of Science ®Google Scholar
• Macchioni P, Catanoso MG, Pipitone N, et al. Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. Rheumatology (Oxford). 2009;48:1566–1569.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 provisional classifi cation criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum. 2012;64:943–954.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classifi cation criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71:484–492.
   PubMed Web of Science ®Google Scholar
• Hutchings A, Hollywood J, Lamping DL, et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum. 2007;57:803–809.
   PubMed Web of Science ®Google Scholar
• Pease CT, Haugeberg G, Montague B, et al. Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. Rheumatology (Oxford). 2009;48:123–127.
   PubMed Web of Science ®Google Scholar
• Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum. 2000;30:17–24.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford). 2010;49:186–190.
   PubMed Web of Science ®Google Scholar
• Camellino D, Cimmino MA. Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis. Rheumatology (Oxford). 2012;51:77–86.
   PubMed Web of Science ®Google Scholar
• Macchioni P, Boiardi L, Catanoso M, et al. Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. Ann Rheum Dis. 2014 Jun;73(6):1190–1193.
   PubMed Web of Science ®Google Scholar
• Frediani B, Falsetti P, Storri L, et al. Evidence for synovitis in active polymyalgia rheumatica: sonographic study in a large series of patients. J Rheumatol. 2002;29:123–130.
   PubMed Web of Science ®Google Scholar
• Cantini F, Salvarani C, Olivieri I, et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol. 2001;28:1049–1055.
   PubMed Web of Science ®Google Scholar
• Koski JM. Ultrasonographic evidence of synovitis in axial joints in patients with polymyalgia rheumatica. Br J Rheumatol. 1992;31:201–203.
   PubMedGoogle Scholar
• Cantini F, Niccoli L, Nannini C, et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol. 2005;23:462–468.
   PubMed Web of Science ®Google Scholar
• Falsetti P, Acciai C, Volpe A, et al. Ultrasonography in early assessment of elderly patients with polymyalgic symptoms: a role in predicting diagnostic outcome? Scand J Rheumatol. 2011;40:57–63.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Pease C, Marzo-Ortega H, et al. Comparison of extracapsular changes by magnetic resonance imaging in patients with rheumatoid arthritis and polymyalgia rheumatica. J Rheumatol. 2001;28:1837–1841.
   PubMed Web of Science ®Google Scholar
• Cantini F, Salvarani C, Niccoli L, et al. Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica. J Rheumatol. 2004;31:120–124.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Barozzi L, Cantini F, et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis. 2008;67:758–761.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Barozzi L, Boiardi L, et al. Lumbar interspinous bursitis in active polymyalgia rheumatica. Clin Exp Rheumatol. 2013 Jul–Aug;31(4):526–531.
   PubMed Web of Science ®Google Scholar
• Sakellariou G, Iagnocco A, Riente L, et al. Ultrasound imaging for the rheumatologist XLIII. Ultrasonographic evaluation of shoulders and hips in patients with polymyalgia rheumatica: a systematic literature review. Clin Exp Rheumatol. 2013 Jan–Feb;31(1):1–7.
   PubMed Web of Science ®Google Scholar
• Cantini F, Salvarani C, Olivieri I, et al. Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. Arthritis Rheum. 2001;44:1155–1159.
   PubMed Web of Science ®Google Scholar
• Blockmans D, De Ceuninck L, Vanderschueren S, et al. Repetitive 18-fl uorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford). 2007;46:672–677.
   PubMed Web of Science ®Google Scholar
• Adams H, Raijmakers P, Smulders Y. Polymyalgia rheumatica and interspinous FDG uptake on PET/CT. Clin Nucl Med. 2012;37:502–505.
   PubMed Web of Science ®Google Scholar
• Palard-Novello X, Querellou S, Gouillou M, et al. Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment. Eur J Nucl Med Mol Imaging. 2016;43:773–779.
   PubMed Web of Science ®Google Scholar
• Rehak Z, Vasina J, Nemec P, et al. Various forms of (18)F-FDG PET and PET/CT findings in patients with polymyalgia rheumatica. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159:629–636.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Kubota K, Takahashi Y, et al. Similarities and differences in fluorodeoxyglucose positron emission tomography/computed tomography findings in spondyloarthropathy, polymyalgia rheumatica and rheumatoid arthritis. Joint Bone Spine. 2013;80:171–177.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Gabriel SE, O’Fallon WM, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995;123:192–194.
   PubMed Web of Science ®Google Scholar
• Muratore F, Pazzola G, Pipitone N, et al. Large-vessel involvement in giant cell arteritis and polymyalgia rheumatica. Clin Exp Rheumatol. 2014 May–Jun;32(3 Suppl 82):S106–S111.
   PubMedGoogle Scholar
• Cimmino MA, Zampogna G, Parodi M. Is FDG-PET useful in the evaluation of steroid-resistant PMR patients? Rheumatology. 2008;47:926–927.
   PubMed Web of Science ®Google Scholar
• Lavado-Pérez C, Martínez-Rodríguez I, Martínez-Amador N, et al. (18)F-FDG PET/CT for the detection of large vessel vasculitis in patients with polymyalgia rheumatica. Rev Esp Med Nucl Imagen Mol. 2015;34:275–281.
   PubMed Web of Science ®Google Scholar
• Wendling D, Blagosklonov O, Boulahdour H, et al. Positron emission tomography: the ideal tool in polymyalgia rheumatica? Joint Bone Spine. 2014;81:381–383.
   PubMed Web of Science ®Google Scholar
• Franzén P, Sutinen S, Von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988. J Rheumatol. 1992;19:273–280.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Storri L, et al. Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthrititis Rheum. 2004;33:294–301.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two diff erent but often overlapping conditions. Semin Arthritis Rheum. 2004;33:289–293.
   PubMed Web of Science ®Google Scholar
• Narváez J, Estrada P, López-Vives L, et al. Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica. Semin Arthritis Rheum. 2015;45:328–333.
   PubMed Web of Science ®Google Scholar
• Deal CL, Meenan RF, Goldenberg DL, et al. The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. Arthritis Rheum. 1985;28:987–994.
   PubMed Web of Science ®Google Scholar
• Olivieri I, Garcia-Porrua C, Padula A, et al. Late onset spondyloarthritis presenting with polymyalgia rheumatica features: description of 7 cases. Rheumatology Int. 2007;27:927–933.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, et al. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol. 2000;27:2179–2184.
   PubMed Web of Science ®Google Scholar
• Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol. 1996;35:1161–1168.
   PubMedGoogle Scholar
• Muller S, Hider SL, Belcher J, et al. Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database. Ann Rheum Dis. 2014;73:1769–1773.
   PubMed Web of Science ®Google Scholar
• Ji J, Liu X, Sundquist K, et al. Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. Rheumatology (Oxford). 2010 Jun;49(6):1158–1163.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Hutchings A, Matteson EL. Polymyalgia rheumatica: the mess we are now in and what we need to do about it. Arthritis Rheum. 2006;55:518–520.
   PubMed Web of Science ®Google Scholar
• Hernandez-Rodriguez J, Cid MC, Lopez-Soto A, et al. Treatment of polymyalgia rheumatica: a systematic review. Arch Intern Med. 2009;169:1839–1850.
   PubMedGoogle Scholar
• Dejaco C, Singh YP, Perel P, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74:1799–1807.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Singh YP, Perel P, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 2015;67:2569–2580.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Dolan AL, Panayi GS, et al. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol. 1998;37:189–195.
   PubMedGoogle Scholar
• Leeb BF, Bird HA, Nesher G, et al. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Ann Rheum Dis. 2003;62:1189–1194.
   PubMed Web of Science ®Google Scholar
• Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis. 2004 Oct;63(10):1279–1283.
   PubMed Web of Science ®Google Scholar
• Binard A, De Bandt M, Berthelot J-M, et al. Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios. Arthritis Rheum. 2007 Apr 15;57(3):481–486.
   PubMed Web of Science ®Google Scholar
• Binard A, Lefebvre B, De Bandt M, et al. Validity of the polymyalgia rheumatica activity score in primary care practice. Ann Rheum Dis. 2009 Apr;68(4):541–545.
   PubMed Web of Science ®Google Scholar
• Cleuziou C, Binard A, De Bandt M, et al. Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice. J Rheumatol. 2012 Feb;39(2):310–313.
   PubMed Web of Science ®Google Scholar
• Kim H-A, Lee J, Ha Y-J, et al. Induction of remission is difficult due to frequent relapse during tapering steroids in Korean patients with polymyalgia rheumatica. J Korean Med Sci. 2012;27:22–26.
   PubMed Web of Science ®Google Scholar
• Ferraccioli G, Salaffi F, De Vita S, et al. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol. 1996;23:624–628.
   PubMed Web of Science ®Google Scholar
• Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004;141:493–500.
   PubMed Web of Science ®Google Scholar
• van der Veen MJ, Dinant HJ, van Booma-Frankfort C, et al. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis. 1996;55:218–223.
   PubMed Web of Science ®Google Scholar
• Cimmino MA, Salvarani C, Macchioni P, et al. Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin Exp Rheumatol. 2008;26:395–400.
   PubMed Web of Science ®Google Scholar
• Adizie T, Christidis D, Dharmapaliah C, et al. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract. 2012 Sep;66(9):906–909.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:1–3.
   Web of Science ®Google Scholar
• Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med. 2007;146:631–639.
   PubMed Web of Science ®Google Scholar
• Catanoso MG, Macchioni P, Boiardi L, et al. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Rheum. 2007;57:1514–1519.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Niccoli L, et al. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol. 2003;30:760–763.
   PubMed Web of Science ®Google Scholar
• Macchioni P, Boiardi L, Catanoso M, et al. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum. 2013 Aug;43(1):113–118.
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Berthelot JM, Cornec D, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016 Feb 29. pii: annrheumdis-2015-208742. doi:10.1136/annrheumdis-2015-208742. Epub ahead of print.
   Web of Science ®Google Scholar
• Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016 Mar 4. pii: S0140-6736(16)00560-2. doi:10.1016/S0140-6736(16)00560-2. Epub ahead of print.
   PubMed Web of Science ®Google Scholar